DV
Dividend Vision

BLTE — Belite Bio, Inc

Belite Bio, Inc (BLTE)

Total return is 1437.3% over the past 4.3 years, 1337.7 points ahead of SPY at 99.6%. Its deepest 1-year drawdown was 29.1%.

Based on the data provided, this appears to be a single-stock holding rather than a diversified ETF. Belite Bio is a biotech equity security that commenced trading in April 2022 and currently does not maintain a distribution yield or regular dividend payments. This holding may appeal to growth-oriented investors seeking exposure to the biotechnology sector, though it lacks the income characteristics typical of dividend-focused strategies.

BLTE key facts

Asset type
Stock
Asset class
Equity
Inception date
04/29/2022
Distribution frequency
None
Last close
$162.80
Market cap
$6,556,305,408
Average volume
228800.0
Beta
-1.225
Payout ratio
0.0
Forward P/E
227.2727
EPS
$-2.68